The SPEQ Library is free, for everyone in life sciences. It explains GxP in plain language: what the regulations require, what FDA actually cites, and how the work gets done. You’ll find standards, topics, step-by-step guides, templates and tools, with no account needed to read them. Whether you’re new to quality or preparing for an inspection, start with what you need today. And when you’re ready to find the gaps in your own quality system before FDA does, the SPEQ workspace is built on the same foundation.
Narrated with a synthetic voice. The transcript is the exact narration script.
What is at stake
An inspection is too late to find out.
A gap FDA finds first can mean a Form FDA 483, a warning letter, or an approval that waits. A gap you find first is a fix on your own schedule.
What FDA has on record
FDA’s public inspection record, searchable in SPEQ. See what FDA cites in the areas you are responsible for:
Issue 1 · issued 2026-10-30 Confidential to client
Engagement · Halden Pharmaceuticals, Site 2Scope
Inspection readiness assessment for drug product manufacturing.
Stage: commercial manufacturingProgram: CP 7356.002Method: IOM Chapter 5
Coverage · CP 7356.002
Quality1 finding
Facilities and equipmentOut
MaterialsCovered
ProductionCovered
Packaging and labelingOut
Laboratory controlCovered
Evidence · Quality system3 exhibits
E-04INV-24-118 OOS investigation
E-05Batch records lots 24-117 and 24-119
E-06Interview note, QA manager
FND-001 · MajorQuality system
The OOS investigation for lot 24-118 did not extend to other lots of the same product, so the discrepancy is not shown to be contained.
21 CFR 211.192E-04E-05ApprovedIn review
R-5304-F497Report ID, on every page. Anyone can verify it, no account needed.Prepared with SPEQ
Step 1 of 6
See the output
Read a sample report.
One full assessment report for a fictional firm, from what to fix first to the evidence behind each finding.
ConsultantsYour name on the report.
Quality teamsKnow before FDA arrives.
Northgate Quality PartnersAssessment report for Halden Pharmaceuticals
Inspection readiness assessment
Program
CP 7356.002
Method
IOM Chapter 5
Findings
3
21 CFR 211.192 The OOS investigation for lot 24-118 did not extend to other lots of the same product.
Free for every practitioner
How mature is your quality system?
Take the free maturity assessment across 12 domains, with a read on FDA’s Quality Management Maturity practice areas. Create a free account to keep your results and build on them.